Human Albumin Csl Behring

Human Albumin Csl Behring is a prescription‑only intravenous solution that contains human plasma protein (human albumin) as its active ingredient; the product’s strength is not specified in the labeling and it is provided as a sterile liquid for infusion. It is manufactured for the European market and is used under medical supervision to support patients with low plasma volume or albumin levels or related conditions.

Human Albumin Csl Behring is indicated for clinical situations where plasma volume expansion or albumin replacement is required.

- Treatment of hypovolemia due to blood loss, dehydration, or sepsis. - Management of hypoalbuminemia associated with liver disease, nephrotic syndrome, or malnutrition. - Fluid resuscitation in patients with extensive burns. - Support for patients in circulatory shock, including septic or traumatic shock. - Adjunct therapy during major surgery or cardiac procedures to maintain oncotic pressure.

Adverse reactions to Human Albumin Csl Behring are generally infrequent but may occur during or after infusion.

Common: - Mild fever or chills. - Transient hypotension or hypertension. - Headache or dizziness. - Nausea or mild gastrointestinal discomfort.

Serious: - Anaphylactic or severe allergic reaction. - Acute hemolysis or renal impairment. - Volume overload leading to pulmonary edema.

Clinicians should evaluate patient history and monitor clinical status when prescribing Human Albumin Csl Behring.

- Verify absence of known hypersensitivity to human albumin or any product component. - Assess fluid balance; avoid use in patients at risk of volume overload or congestive heart failure. - Use caution in individuals with renal or hepatic impairment, adjusting volume as needed. - Monitor vital signs and serum albumin levels during infusion. - Ensure proper aseptic technique to prevent contamination. - Consider contraindication in patients with severe hypervolemia or uncontrolled hypertension.

Human Albumin Csl Behring may interact with other therapies that affect fluid status or immune response.

Avoid: - Concurrent administration of other volume expanders (e.g., synthetic colloids) without clear clinical justification. - Simultaneous infusion of blood products that are not compatible, which may increase risk of hemolysis.

Use with caution: - Diuretics, as they may alter intravascular volume and require dose adjustments. - Vasopressors, because rapid volume changes can affect blood pressure control. - Immunosuppressive agents, which could mask signs of an allergic reaction. - Anticoagulants, due to potential changes in plasma protein binding.